Background: Cluster subcutaneous immunotherapy can be identified to have the ideal schedule that allows the dose considered effective to be reached in the shortest possible time with the fewest adverse effects. There are very few studies on Cluster subcutaneousimmunotherapy in India. Methodology: The present study was conducted in Allergy clinic, KIMS Hospital & Research Centre, Bangalore for 18 months period. 40 Naso bronchial allergy patients in the 18–60 years age group who were positive for aeroallergens in skin prick test were recruited for cluster subcutaneous immunotherapy and followed for 12 months with symptom and treatment diary. Results: Out of 40 patients, the majority, 30 (75.00%) patients were sensitive to house dust mites. All patients tolerated cluster SCIT none of them had any adverse reaction and there was significant decrease in both symptom-score and treatment score in these patients. Conclusion: Cluster SCIT regimen has excellent safety, tolerability and clinical efficacy among Naso bronchial allergy patients.
